Q4 2025 AngioDynamics Inc Earnings Call Transcript
Key Points
- AngioDynamics Inc (ANGO) reported a strong fourth quarter with total revenue of $80.2 million, representing a growth of over 12% year-over-year.
- The Med Tech segment showed impressive growth, with a 22% increase in revenue, driven by products like Auryon and mechanical thrombectomy devices.
- The Auryon platform has achieved 16 consecutive quarters of double-digit growth, highlighting its strong market position and adoption.
- The company has successfully expanded its international market presence, particularly in Europe, following the CE mark approval for Auryon.
- AngioDynamics Inc (ANGO) has made significant progress in clinical trials and regulatory approvals, positioning products like NanoKnife for future growth with new reimbursement codes effective in 2026.
- The company faced a $1.6 million impact from tariffs in the fourth quarter, affecting gross margins and profitability.
- Despite growth in the Med Tech segment, the NanoKnife revenue saw a decrease of 2.5% due to a decline in capital sales.
- The company anticipates a continued impact from tariffs in fiscal year 2026, with an estimated cost of $4 million to $6 million.
- There is uncertainty regarding the regulatory pathway for the blood return feature of the AlphaVac product, which could impact its market adoption.
- The Med Device segment showed minimal growth, with only a 0.8% increase in revenue for the fiscal year 2025.
Good morning, and welcome to the AngioDynamics fiscal year 2025 fourth quarter earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
The news release detailing AngioDynamics fiscal 2025 fourth quarter and full year results crossed the wire earlier this morning and is available on the company's website. This conference call is also being broadcast live over the Internet at the Investors section of the company's site at www.angiodynamics.com. A webcast replay of the call will be available at the same site approximately one hour after the end of today's call.
Before we begin, I'd like to caution listeners that during the course of this conference call, the company will make projections or forward-looking statements regarding future events, including statements about expected revenue, adjusted earnings and gross margins for fiscal year 2026 as well as trends that may continue. Management encourages you to review the company's past and future filings with the SEC, including, without
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
